ToxNav® Advantage™ Launches in the U.S. at ASCO GI 2026
Mira Precision Health announced the U.S. launch of ToxNav® Advantage™, a clinically validated pharmacogenomic assay for fluoropyrimidine toxicity risk.
Source: Oxford Cancer Biomarkers / Mira Precision Health